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ABSTRACT: Cytosolic phospholipase A2 (GIVA cPLA2) has
attracted great interest as a medicinal target because it initiates
the eicosanoid cascade and is involved in a number of
inflammatory diseases. As a consequence, the development of
potent synthetic inhibitors is of great importance. We have
developed highly potent 2-oxoester inhibitors of GIVA cPLA2
presenting XI(50) values between 0.000019 and 0.000066. We
demonstrate that the 2-oxoester functionality is essential for in
vitro inhibitory activity, making these inhibitors useful
research reagents. However, their high reactivity results in
rapid degradation of the inhibitors in human plasma, limiting
their pharmaceutical utility without further modification.
■ INTRODUCTION
Phospholipases A2 (PLA2s) have attracted great interest as
medicinal targets for more than 20 years because they are
involved in a number of inflammatory diseases.1 Among this
superfamily of enzymes,2 cytosolic PLA2 (GIVA cPLA2) stands
out because it exhibits a marked preference for the hydrolysis
of arachidonic acid at the sn-2 position of phospholipid
substrates releasing arachidonic acid and initiating the
eicosanoid cascade.3 Both the physiological function and the
role of cytosolic PLA2 have been recently summarized by
Leslie.4 Due to the involvement of PLA2s in various
inflammatory diseases, many synthetic inhibitors have been
developed in both academia and pharmaceutical companies.1
Two recent review articles discuss the classes of PLA2
inhibitors and highlight the in vitro activities and selectivity
and the in vivo studies in animal models.5,6
Most recently, a randomized double-blind placebo-con-
trolled dose-escalation first-in-man study to assess the safety
and efficacy of a topical cytosolic PLA2 inhibitor AVX001 (1,
Figure 1) in patients with mild-to-moderate plaque psoriasis
has demonstrated that treatment with AVX001 is well tolerated
in doses up to 5%.7 Pharmacological inhibition of GIVA cPLA2
by inhibitor 2 (Figure 1) blocked Streptococcus pneumoniae-
induced polymorphonuclear cells transepithelial migration in
vitro, suggesting that this enzyme plays a crucial role in
eliciting pulmonary inflammation during pneumococcal
infection.8 The daily administration of the indole-based
inhibitor ASB14780 (3, Figure 1), which had been developed
by Tomoo and colleagues,9 markedly ameliorated liver injury
and hepatic fibrosis following 6 weeks of treatment with CCl4,
indicating that a GIVA cPLA2 inhibitor could be useful for the
treatment of nonalcoholic fatty liver diseases, including fatty
liver and hepatic fibrosis.10 A few years ago, we presented new
thiazolyl ketones as inhibitors of GIVA cPLA2 and
demonstrated the in vivo anti-inflammatory activity of inhibitor
GK470 (4, Figure 1) in a collagen-induced arthritis model.11
The anti-angiogenic effects of this inhibitor (now named as
AVX235) in a patient-derived triple-negative basal-like breast
cancer model was evaluated and significant tumor growth
inhibition was observed after 8 days of treatment.12 Most
recent findings showed that blockage of GIVA cPLA2 by either
inhibitor 2 or pyrrophenone (5, Figure 1) sensitized aggressive
breast cancer to doxorubicin by suppressing ERK and mTOR
kinases.13
All of the above-described recent applications of synthetic
GIVA cPLA2 inhibitors highlight the importance of identifying
new highly potent inhibitors to regulate the activity of GIVA
cPLA2. Last year, we reported the development of a novel class
of GIVA cPLA2 inhibitors, namely, 2-oxoesters.
14 2-Oxoester
GK452 (6, Figure 1), containing a biphenyl system and a free
carboxyl group, led to highly potent and selective GIVA cPLA2
in vitro inhibition (XI(50) 0.000078). The aim of the present
work was to further understand the characteristics of 2-
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oxoesters and explore the possibility of producing more potent
GIVA cPLA2 inhibitors.
■ RESULTS AND DISCUSSION
Synthesis of Inhibitors. To extend the structure−activity
relationship studies on 2-oxoester inhibitors, we (a) shortened
the length between the activated carbonyl group and the
biphenyl functionality, (b) replaced the biphenyl system with a
para-alkoxy-substituted phenyl group, and (c) explored the
importance of the activated carbonyl group. To this end, a
variety of 2-substituted carboxylic acids, required for the target
compounds, were synthesized as described in Scheme 1.
Figure 1. Structures of known GIVA cPLA2 inhibitors.
Scheme 1
aReagents and conditions: (a) (C2H5O)2P(O)CH2CHCHCO2C2H5, LiOH·H2O, tetrahydrofuran (THF), mol. sieves; (b) H2, 10% Pd/C,
EtOH; (c) DIBALH, Et2O; (d) C6H5I(O2CCH3)2, cat. (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl or (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl
(TEMPO), CH2Cl2; (e) (i) 4 N aq. NaHSO3, CH2Cl2 (ii) 4 N aq. KCN; (f) 4 N HCl/MeOH; (g) 50% aq. NaOH, 1,4-dioxane; (h)
diethylaminosulfur trifluoride (DAST), CH2Cl2.
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The synthesis of carboxylic acids 13, 15, and 16, bearing a 4-
butoxy-phenyl group, started with the Wadsworth−Horner−
Emmons olefination reaction of aldehydes 7a, 7b15 with
triethyl phosphonocrotonate to give the corresponding
unsaturated esters 8a,b, which were hydrogenated to
compounds 9a,b. The reduction of 9a led to alcohol 10,
which subsequently provided cyanohydrin 11. Subsequent
treatment with HCl in methanol gave 2-hydroxy methyl ester
12, which was then saponified to 2-hydroxy acid 13 by
treatment with aqueous NaOH. Treatment of 12 with the
fluorinating agent diethylaminosulfur trifluoride (DAST)16
resulted in 2-fluoro methyl ester 14, consequently providing 2-
fluoro carboxylic acid 15 after saponification. The carboxylic
acid 16 was also obtained by alkaline hydrolysis of 9b. The
synthesis of 2-hydroxy acid 20 was accomplished by similar
procedures starting from aldehyde 17,17 as depicted in Scheme
2.
The key step in the synthesis of 2-oxoesters was the reaction
between cesium salt of 2-hydroxy carboxylic acids with
appropriate tert-butyl bromoalkanoate 22a,b14 (Scheme 3).
2-Hydroxy esters 23a−d, obtained from 2-hydroxy carboxylic
acids 13, 20, and the previously synthesized 21,14 were then
oxidized to the corresponding 2-oxoesters 24a−d using the
Dess−Martin periodinane reagent. Cleavage of tert-butyl
protecting group led to the target compounds 25a−d (Scheme
3).
Likewise, reaction of 2-fluoro carboxylic acid 15 and acid 16
with tert-butyl bromopentanoate (22b) resulted in derivatives
26a,b, and subsequently, after the removal of tert-butyl group,
to the desired products 27a,b (Scheme 4). Finally, the
synthesis of 2-oxoacid 29 was accomplished as shown in
Scheme 5 by saponification of the corresponding 2-oxoester 28
under mild conditions.
Scheme 2
aReagents and conditions: (a) (i) 4 N aq. NaHSO3, CH2Cl2, and (ii) 4 N aq. KCN; (b) 4 N HCl/MeOH; and (c) 50% aq. NaOH, 1,4-dioxane.
Scheme 3
aReagents and conditions: (a) 20% aq. Cs2CO3, N,N-dimethylformamide (DMF); (b) Dess−Martin periodinane, CH2Cl2; and (c) 50%
trifluoroacetic acid (TFA)/CH2Cl2.
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In Vitro Inhibition of GIVA cPLA2, GVIA iPLA2, and GV
sPLA2. All of the new compounds synthesized were tested for
in vitro inhibition of human GIVA cPLA2, calcium-
independent phospholipase A2 (GVIA iPLA2), and secreted
phospholipase A2 (GV sPLA2) using previously described
mixed micelle-based assays.18−20 The inhibition results are
presented in Table 1, either as percent inhibition or as XI(50)
values. At first, the percent of inhibition for each PLA2 enzyme
at a high mole fraction (0.091) of each inhibitor was
determined. Then, the XI(50) values were measured for
compounds that displayed more than 95% inhibition. The
XI(50) is the mole fraction of the inhibitor in the total
substrate interface required to inhibit the enzyme by 50%.
Because it is an important property of GIVA cPLA2
inhibitors, the Clog P values for all the compounds tested,
calculated by ChemDraw, are also included in Table 1. The
Clog P value is a measure of hydrophobicity and represents the
calculated partition coefficient in octanol/water on a
logarithmic scale.
Inhibitor 6 (GK452) (XI(50) 0.000078)
14 is included in
Table 1 for comparison purposes. When the distance between
the oxoester functionality and the biphenyl system was
decreased from four to two carbon atoms (compound 25c
(GK482) and compound 25d (GK483)), the inhibitory
potency against GIVA cPLA2 considerably decreased. This
decrease was 1 order of magnitude in the case of a four-carbon
linker (compound 25c XI(50) 0.00041), further decreasing (2
orders of magnitude) when the linker was further shortened
(25d XI(50) 0.0012). These results are in accordance with our
previous results14 and confirm that the optimum distance
between the free carboxyl group and the oxoester functionality
corresponds to four carbon atoms. In addition, compound 25c
lost the selectivity because the inhibition of GVIA iPLA2 was
observed (XI(50) 0.0030). Thus, the four-carbon linker was
maintained for all the other derivatives. The optimum length of
the linker may be correlated with stereochemical reasons,
rather than hydrophobicity.
Interestingly, when one ring of the biphenyl system was
replaced by a para-hexyloxy group, an increase in the inhibitor
potency against GIVA cPLA2 was observed. Compound 25b
(GK484) is the most potent inhibitor of GIVA cPLA2 ever
reported with a XI(50) value of 0.000019, 4 times more potent
than 6. However, the replacement of the phenyl ring by the
hexyloxy group resulted in an increase in the Clog P value
(from 4.70 for 6 to 5.37 for 25b). Thus, we shortened the
hexyloxy chain to butyloxy one. Compound 25a (GK504)
(XI(50) 0.000066) is 3 times less potent than 25b, but still
slightly more potent than 6. In addition, its Clog P value (4.31)
is lower than 5, which is favorable because Lipinski’s “rule of 5”
predicts that poor absorption or permeation is more likely
when CLog P is greater than 5.21 Neither 25b nor 25a
presented significant inhibition of GVIA iPLA2 (86 and 77%,
respectively, at a high mole fraction 0.091). In our experience,
compounds that show inhibition of PLA2 less than 90% at the
highest concentration tested (which corresponds to about 50
μM inhibitor) always exhibit XI(50) values greater than
0.01.11,22 The GIVA cPLA2 inhibitor 25b with a XI(50)
0.000019 is the most potent inhibitor of GIVA cPLA2 ever
reported and is at least 500-fold selective over GVIA iPLA2.
To confirm the importance of the oxoester functionality, we
removed the activated carbonyl group. Compound 27a
(GK505) abolished the inhibitory potency against GIVA
cPLA2. Because the only structural difference between 27a and
25a is the lack of the carbonyl group, a comparison of the
inhibitory potencies of 25a and 27a makes it clear that the
carbonyl group of the oxoester functionality is essential for
GIVA cPLA2 inhibition. To explore if an electron-withdrawing
group at position 2 could contribute to the inhibitory potency,
the fluoro derivative 27b (GK506) was studied. However,
again, no inhibition of GIVA cPLA2 was observed. Finally, 2-
oxoacid 29 (GK511) was evaluated in vitro and only a very
weak inhibition of GIVA cPLA2 was recorded (55% at a high
mole fraction 0.091). Because this 2-oxoacid is a fragment of 2-
oxoester 25a, it is clear that the oxoester functionality is
absolutely necessary for the inhibition.
Plasma Stability Studies. Determination of the stability
of new chemical entities in plasma is important, as compounds
(with the exception of pro-drugs), which rapidly degrade in
plasma, generally show poor in vivo performance.23 The
stability of compounds 25a, 25b, and 27a in human plasma
was studied in a time-dependent manner. Our aim was to
understand the difference between the two highly potent 2-
oxoesters GIVA cPLA2 inhibitors 25a and 25b in comparison
to compound 27a lacking the activated carbonyl group. A
liquid chromatography-high resolution mass spectrometry
(LC-HRMS) method was developed to measure the inhibitor
levels in plasma. All of the HRMS spectra were obtained in
electrospray ionization (ESI) negative ion mode. The
molecular ion of inhibitor 25b (GK484) was recorded at m/
Scheme 4
aReagents and conditions: (a) 20% aq. Cs2CO3, DMF and (b) 50%
TFA/CH2Cl2.
Scheme 5
aReagents and conditions: (a) Dess−Martin periodinane and (b) 20%
aq. Cs2CO3, MeOH.
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z 405.2253 (Figure 2A), whereas in the MS/MS spectrum
(Figure 2B), the most intense signal corresponds to the loss of
C5H8O2 (−100.0524), indicating the fragmentation of the
ester bond. The HRMS spectra of inhibitors 25a and 27a are
shown in the Supporting Information. In all cases of 2-oxoester
inhibitors, the fragmentation of the ester bond was observed.
Plasma samples incubated with each inhibitor were taken at 0,
15, 30, and 60 min and the molecular ion of each inhibitor was
used to estimate the inhibitor level. The stability results are
presented in Figure 2C as percent parent compound remaining
at each time point. Inhibitors 25a (GK504) and 25b (GK484),
containing the 2-oxo group, are not detectable in the plasma
samples after 30 min, in contrast to 27a (GK505), whose
percentage remains close to 100% after 1 h. Apparently, the
activated carbonyl group of the 2-oxoester functionality of
inhibitors 25a and 25b increases the chemical reactivity of the
ester bond toward hydrolysis in comparison to the less active
simple ester bond of inhibitor 27a. These results indicate that
the activated carbonyl group, which is essential for the enzyme
inhibition, makes the compounds susceptible to rapid
degradation in human plasma. A compound like 27a, lacking
the activated carbonyl group, is rather stable in plasma,
however lacking the inhibitory properties.
■ CONCLUSIONS
In conclusion, a number of new 2-oxoesters and analogues
were synthesized. GK484 is the most potent inhibitor of GIVA
cPLA2 ever reported with a XI(50) value of 0.000019. The
study of the in vitro inhibitory activity highlighted the
importance of the 2-oxoester group for the inhibitory potency
against GIVA cPLA2. The stability studies of 2-oxoesters in
human plasma indicate that a fine-tuning between the
reactivity of the carbonyl group and its stability will be needed
in order for 2-oxoesters to be used in vivo as pharmacological
agents.
■ EXPERIMENTAL SECTION
General. Merck Silica Gel 60254 aluminum plates and
Silica Gel 60 (70−230 or 230−400 mesh) were used for thin-
layer chromatography and chromatographic purification of
products, respectively. For visualizing spots, UV light and/or
phosphomolybdic acid was employed. Melting points were
estimated by a Büchi 530 apparatus and uncorrected. 1H, 13C,
and 19F NMR spectra were recorded on Varian Mercury at
200, 50, and 188 MHz, respectively. CDCl3 was used as the
solvent. Chemical shifts are given in ppm and coupling
constants (J) in Hz. Peak multiplicities are typified as follows:
s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q,
quartet; qt, quintet; and m, multiplet. Dichloromethane was
dried by standard procedures and stored over molecular sieves.
No further purification of other solvents and chemicals was
needed. The HRMS spectra were recorded on a Bruker Maxis
Impact QTOF Spectrometer.
Table 1. In Vitro Inhibitory Potency and Selectivity of 2-Oxoesters
aCalculated with ChemDraw. b% Inhibition at 0.091 mol fraction of each inhibitor.
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Synthesis. Compound 7a was commercially available, and
compounds 7b,15 17,17 and 2114 have been described
elsewhere and their analytical data are in accordance with
literature.
General Procedure for Synthesis of Unsaturated Esters
8a,b. To a flame-dried, round-bottomed flask containing
powdered molecular sieves (1 g), LiOH·H2O (1.5 mmol, 36
mg) and a solution of aldehyde 7a,b (1 mmol) in dry THF (10
mL) were added under Ar atmosphere. Triethyl 4-
phosphonocrotonate (1.5 mmol, 375 mg) was added and the
mixture was left under reflux overnight. The reaction mixture
was filtered through celite and the solvent was evaporated
under reduced pressure. The products were obtained after
trituration with MeOH.
Ethyl (2E,4E)-5-(4-Butoxyphenyl)penta-2,4-dienoate (8a).
Yield 60%; white solid; mp 57−60 °C; 1H NMR (200 MHz,
CDCl3): δ 7.49−7.18 (m, 3H, arom, CH), 6.89−6.50 (m,
4H, arom, 2 ×CH), 5.87 (d, J = 15.2 Hz, 1H,CH), 4.17
(q, J = 7.1 Hz, 2H, CH2OCO), 3.87 (t, J = 6.4 Hz, 2H,
CH2O), 1.82−1.60 (m, 2H, CH2), 1.47−1.33 (m, 2H, CH2),
1.25 (t, J = 7.1 Hz, 3H, CH3CH2OCO), 0.92 (t, J = 7.3 Hz,
3H, CH3);
13C NMR (50 MHz, CDCl3) δ 167.3, 160.2, 145.3,
140.4, 128.9, 128.7, 124.1, 120.1, 114.9, 67.9, 60.3, 31.5, 19.4,
14.6, 14.1; Anal. Calcd for C17H22O3: C, 74.42; H, 8.08; found:
C, 74.06; H, 8.53.
Ethyl (2E,4E)-6-(4-Butoxyphenyl)hexa-2,4-dienoate (8b).
Yield 50%; white solid; mp 62−65 °C 1H NMR (200 MHz,
CDCl3): δ 7.36−7.17 (m, 1H,CH), 7.03 (d, J = 8.4 Hz, 2H,
arom) 6.81 (d, J = 8.4 Hz, 2H, arom), 6.15 (d, J = 8.0 Hz, 2H,
Figure 2. Precursor ion (A) and MS/MS HRMS spectrum (B) of inhibitor GK484. Time-dependent degradation of inhibitors GK484, GK504, and
GK505 in human plasma (C).
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2xCH), 5.79 (d, J = 15.3 Hz, 1H, CH), 4.16 (q, J = 7.1
Hz, 2H, CH2OCO), 3.89 (t, J = 6.3 Hz, 2H, CH2O), 3.59−
3.30 (m, 2H, PhCH2), 1.81−1.63 (m, 2H, CH2), 1.45 (m, 2H,
CH2), 1.25 (t, J = 7.1 Hz, 3H, CH3CH2OCO), 0.96 (t, J = 7.3
Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ 166.3, 157.2,
143.9, 142.2, 129.9, 128.9, 128.4, 119.5, 66.9, 59.5, 113.9, 37.8,
30.8, 18.7, 13.7, 13.3; Anal. Calcd for C18H24O3: C, 74.97; H,
8.39; found: C, 74.64; H, 8.72.
General Procedure for Hydrogenation. To a solution of
unsaturated esters 8a,b (1 mmol) in EtOH (10 mL), 10% Pd/
C was added and the mixture stirred overnight under H2
atmosphere. The reaction mixture was filtered through celite
and concentrated in vacuo to isolate the saturated product
9a,b.
Ethyl 5-(4-Butoxyphenyl)pentanoate (9a). Yield 99%;
colorless oil; 1H NMR (200 MHz, CDCl3): δ 7.07 (d, J =
8.6 Hz, 2H, arom), 6.81 (d, J = 8.6 Hz, 2H, arom), 4.12 (q, J =
7.1 Hz, 2H, CH2OCO), 3.92 (t, J = 6.4 Hz, 1H, CH2O), 2.56
(t, J = 6.9 Hz, 2H, PhCH2), 2.31 (t, J = 7.0 Hz, 2H, CH2CO),
1.84−1.70 (m, 2H, CH2), 1.69−1.56 (m, 4H, CH2), 1.56−1.38
(m, 2H, CH2), 1.24 (t, J = 7.1 Hz, 3H, CH3CH2O), 0.97 (t, J =
7.3 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ 173.8,
157.5, 134.2, 129.4, 114.5, 67.8, 60.4, 34.9, 34.4, 31.7, 31.4,
24.8, 19.5, 14.5, 14.1; Anal. Calcd for C17H26O3: C, 73.35; H,
9.41; found: C, 73.07; H, 9.69.
Ethyl 6-(4-Butoxyphenyl)hexanoate (9b). Yield 99%;
colorless oil; 1H NMR (200 MHz, CDCl3): δ 7.08−6.94 (d,
J = 8.3 Hz, 2H, arom), 6.85−6.67 (d, J = 8.6 Hz, 2H, arom),
4.43−4.10 (m, 2H, CH2OCO), 3.87 (t, J = 6.4 Hz, 2H,
CH2O), 2.64−2.39 (m, 2H, PhCH2), 2.33−2.18 (m, 2H,
CH2CO), 1.86−1.30 (m, 10H, 5 × CH2), 1.22 (t, J = 7.2 Hz,
3H, CH3CH2O), 0.94 (t, J = 7.2 Hz, 3H, CH3);
13C NMR (50
MHz, CDCl3): δ 173.5, 157.0, 134.1, 129.0, 114.3, 67.3, 59.9,
34.6, 34.0, 31.3, 29.6, 28.4, 24.6, 19.1, 14.0, 13.7; Anal. Calcd
for C18H28O3: C, 73.93; H, 9.65; found: C, 73.72; H, 9.82.
5-(4-Butoxyphenyl)pentan-1-ol (10). A solution of 9a (1
mmol, 0.27 g) in anhydrous Et2O (10 mL) under Ar was
cooled at 0 °C. DIBALH (1.2 mmol, 1.2 mL) was added
dropwise and the mixture was left at room temperature for 30
min. The reaction was quenched by adding ice at 0 °C and left
to stir for 30 min. The mixture was filtered through celite and
concentrated under reduced pressure. The residue was purified
by column chromatography, using EtOAc/petroleum ether (bp
40−60 °C) 3:7 as eluent. Yield 90%; colorless oil; 1H NMR
(200 MHz, CDCl3): δ 7.07 (d, J = 8.5 Hz, 2H, arom), 6.81 (d,
J = 8.6 Hz, 2H, arom), 3.93 (t, J = 6.5 Hz, 2H, CH2O), 3.60 (t,
J = 6.5 Hz, 2H, CH2OH), 2.50 (t, J = 6.4 Hz, 2H, PhCH2),
2.08 (brs, 1H, OH), 1.86−1.30 (m, 10H), 0.97 (t, J = 7.3 Hz,
3H, CH3);
13C NMR (50 MHz, CDCl3): δ 157.4, 134.7, 129.4,
114.5, 67.9, 63.0, 35.2, 32.8, 31.8, 31.6, 25.6, 19.5, 14.1; Anal.
Calcd for C15H24O2: C, 76.23; H, 10.24; found: C, 76.09; H,
10.32.
6-(4-Butoxyphenyl)-2-hydroxyhexanenitrile (11). To a
stirring solution of alcohol 10 (1 mmol, 0.24 g) in dry
CH2Cl2 (10 mL), iodobenzene diacetate (1.2 mmol, 0.39 g)
and a catalytic amount of TEMPO (10%, 0.024 g) were added
and the reaction mixture was left stirring at room temperature
for 1 h. The reaction mixture was washed consecutively with
10% aqueous Na2S2O3 (10 mL), 10% aqueous NaHCO3 (10
mL), and brine (10 mL), dried over Na2SO4, and concentrated
in vacuo. The aldehyde was then dissolved in CH2Cl2 (1.5 mL)
and 4 N aqueous NaHSO3 (2 mmol, 0.5 mL) and the mixture
was left stirring for 30 min at room temperature. The organic
solvent was removed under reduced pressure and H2O (1.5
mL) was added. The mixture was cooled down to 0 °C and 4
N aqueous KCN (0.5 mL) was added dropwise within 2 h
under vigorous stirring, followed by stirring overnight at room
temperature. Then, H2O (10 mL) was added and extracted
with CH2Cl2 (3 × 10 mL). The combined organic layers were
washed with brine, dried over Na2SO4, and concentrated under
reduced pressure. The residue was purified by column
chromatography with EtOAc/petroleum ether (bp 40−60
°C) 3:7 as eluent. Yield 71%; colorless oil; 1H NMR (200
MHz, CDCl3): δ 7.08 (d, J = 8.3 Hz, 2H, arom), 6.83 (d, J =
8.3 Hz, 2H, arom), 4.53−4.38 (m, 1H, CH), 3.95 (t, J = 6.4
Hz, 2H, CH2O), 2.58 (t, J = 7.1 Hz, 2H, PhCH2), 1.93−1.38
(m, 10H, 5 × CH2), 0.98 (t, J = 7.3 Hz, 3H, CH3);
13C NMR
(50 MHz, CDCl3): δ 157.5, 134.2, 129.5, 120.4, 114.7, 68.0,
61.4, 35.3, 35.0, 31.6, 31.3, 24.4, 19.5, 14.2; MS (ESI) m/z
(%): 279 ([M + NH4]
+, 100); Anal. Calcd for C16H23NO2: C,
73.53; H, 8.87; N, 5.36; found: C, 73.32; H, 9.03; N, 5.18.
4-([1,1′-Biphenyl]-4-yl)-2-hydroxybutanenitrile (18). To a
stirring solution of aldehyde 17 (1.0 mmol) in CH2Cl2 (1.5
mL), an aqueous solution of NaHSO3 6 M (0.25 mL, 1.5
mmol) was added and the mixture was left stirring for 30 min
at room temperature. The organic solvent was evaporated
under reduced pressure and H2O (5 mL) was added. The
mixture was cooled down to 0 °C and an aqueous solution of
KCN 6 M (0.25 mL, 1.5 mmol) was added dropwise under
vigorous stirring. The reaction was left stirring for 18 h at room
temperature and then the mixture was extracted with CH2Cl2
(2 × 20 mL), washed with brine, and dried over Na2SO4. The
organic solvent was evaporated under reduced pressure and the
residue was purified by flash column chromatography using
EtOAc/petroleum ether (bp 40−60 °C) 2.5:7.5 as eluent.
Yield 59%; white solid; mp 93−95 °C; 1H NMR (200 MHz,
CDCl3): δ = 7.66−7.13 (m, 9H, arom), 4.16 (q, J = 7.2 Hz,
1H, CH), 3.76 (brs, 1H, OH), 2.90 (t, J = 7.4 Hz, 2H,
PhCH2), 2.22−2.13 (m, 2H, CH2). 13C NMR (50 MHz,
CDCl3): δ 140.6, 139.3, 138.6, 128.8, 128.7, 127.3, 127.1,
126.9, 119.9, 60.2, 36.4, 30.2; MS (ESI) m/z (%): 255 ([M +
NH4]
+, 100); Anal. Calcd for C16H15NO: C, 80.98; H, 6.37; N,
5.90; found: C, 80.64; H, 6.68; N, 5.73.
General Procedure for Synthesis of 2-Hydroxy Esters 12
and 19. Cyanohydrins 11 and 18 (1 mmol) were dissolved in
4 N HCl/MeOH (10 mL) and the reaction mixture stirred for
24 h at room temperature. The organic solvent was evaporated
under reduced pressure. The residue was dissolved in Et2O (10
mL) and re-evaporated. Dilution and evaporation were
repeated twice. The product was purified by flash column
chromatography using EtOAc/petroleum ether (bp 40−60
°C) 2:8 as eluent.
Methyl 6-(4-Butoxyphenyl)-2-hydroxyhexanoate (12).
Yield 65%; colorless oil; 1H NMR (200 MHz, CDCl3): δ
7.07 (d, J = 8.6 Hz, 2H, arom), 6.81 (d, J = 8.6 Hz, 2H, arom),
4.25−4.10 (m, 1H, CH), 3.93 (t, J = 6.5 Hz, 2H, CH2O), 3.77
(s, 3H, OCH3), 2.83 (bs, 1H, OH), 2.63−2.48 (m, 2H,
PhCH2), 1.93−1.37 (m, 10H, CH2), 0.97 (t, J = 7.3 Hz, 3H,
CH3);
13C NMR (50 MHz, CDCl3): δ 176.0, 157.4, 134.5,
129.4, 114.5, 70.6, 67.9, 52.8, 35.3, 35.0, 34.5, 31.6, 24.6, 19.5,
14.1; MS (ESI) m/z (%): 312 ([M + NH4]
+, 100); Anal. Calcd
for C17H26O4: C, 69.36; H, 8.90; found: C, 69.18; H, 9.02.
Methyl 4-([1,1′-Biphenyl]-4-yl)-2-hydroxybutanoate (19).
Yield 64%; colorless oil; 1H NMR (200 MHz, CDCl3): δ
7.64−7.22 (m, 9H, arom), 4.25 (q, J = 4.0 Hz, 1H, CH), 3.77
(s, 3H, OCH3), 2.84 (t, J = 8.2 Hz, 2H, PhCH2), 2.30−1.84
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(m, 2H, CH2);
13C NMR (50 MHz, CDCl3): δ 175.6, 140.9,
140.1, 138.9, 129.0, 128.7, 127.1, 127.0, 126.9, 69.6, 52.5, 35.8,
30.6; MS (ESI) m/z (%): 288 ([M + NH4]
+, 100); Anal. Calcd
for C17H18O3: C, 75.53; H, 6.71; found: C, 75.32; H, 6.84.
Methyl 6-(4-Butoxyphenyl)-2-fluorohexanoate (14). A
solution of diethylaminosulfur trifluoride (1.1 mmol, 0.15
mL) in CH2Cl2 (0.23 mL) was added to a flame-dried flask,
under Ar atmosphere, and cooled down to −78 °C. A solution
of ester 12 (1 mmol, 0.29 g) in anhydrous CH2Cl2 (0.3 mL)
was added dropwise and the reaction stirred for 2 h at −78 °C
and then overnight at room temperature. The reaction mixture
was then concentrated under reduced pressure and the product
was purified by column chromatography using EtOAc/
petroleum ether (bp 40−60 °C) 2:8 as eluent. Yield 55%;
yellowish oil; 1H NMR (200 MHz, CDCl3): δ 7.09 (d, J = 8.5
Hz, 2H, arom), 6.83 (d, J = 8.5 Hz, 2H, arom), 4.90 (dt, J =
49.0 Hz, J = 6.1 Hz, 1H, CHF), 3.94 (t, J = 6.4 Hz, 2H,
CH2O), 3.77 (s, 3H, OCH3), 2.58 (t, J = 7.3 Hz, 2H, PhCH2),
1.94−1.40 (m, 10H, CH2), 0.99 (t, J = 7.3 Hz, 3H, CH3); 13C
NMR (50 MHz, CDCl3): δ 170.3 (d, J = 23.9 Hz), 157.1,
133.7, 129.0, 114.1, 88.7 (d, J = 184.0 Hz), 67.4, 52.02, 34.5,
32.1 (d, J = 21.0 Hz), 31.2, 31.0, 23.8 (d, J = 3 Hz), 19.1, 13.7;
19F NMR (188 MHz, CDCl3): δ −150.03 (qt, J = 24.4 Hz).
MS (ESI) m/z (%): 314 ([M + NH4]
+, 100); Anal. Calcd for
C17H25FO3: C, 68.89; H, 8.50; found: C, 68.66; H, 8.71.
General Procedure for Saponification. To a stirring
solution of methyl esters 9b, 12, 14, and 19 (1 mmol) in
1,4-dioxane (10 mL), 2 N aqueous NaOH (2.0 mL) was added
and the mixture stirred at room temperature overnight. The
solvent was evaporated under reduced pressure and the residue
was dissolved in H2O (10 mL) and extracted with Et2O (3 ×
10 mL). The aqueous layer was then acidified with 2 N HCl
(4.0 mL) and extracted with EtOAc (3 × 10 mL) followed by
drying over Na2SO4 and concentrating in vacuo.
6-(4-Butoxyphenyl)-2-hydroxyhexanoic Acid (13). Yield
95%; yellowish solid; mp 88−90 °C; 1H NMR (200 MHz,
CDCl3): δ 7.06 (d, J = 8.6 Hz, 2H, arom), 6.81 (d, J = 8.6 Hz,
2H, arom), 4.28−4.22 (m, 1H, CH), 3.93 (t, J = 6.5 Hz, 2H,
CH2O), 2.55 (t, J = 7.2 Hz, 2H, PhCH2), 1.95−1.37 (m, 10H,
5 × CH2), 0.97 (t, J = 6.4 Hz, 3H, CH3);
13C NMR (50 MHz,
CDCl3) δ 180.0, 157.4, 134.5, 129.4, 114.6, 70.4, 68.0, 35.0,
34.2, 31.6, 24.7, 19.5, 14.1; MS (ESI) m/z (%): 279 ([M −
H]−, 100); Anal. Calcd for C16H24O4: C, 68.55; H, 8.63;
found: C, 68.32; H, 8.75.
6-(4-Butoxyphenyl)-2-fluorohexanoic Acid (15). Yield
95%; yellowish solid; mp 65−67 °C; 1H NMR (200 MHz,
CDCl3): δ 9.90 (s, 1H, COOH), 7.08 (d, J = 8.5 Hz, 2H,
arom), 6.83 (d, J = 8.6 Hz, 2H, arom), 4.95 (dt, J = 48.6 Hz,
6.4 Hz, 1H, CHF), 3.95 (t, J = 6.5 Hz, 2H, CH2O), 2.58 (t, J =
7.2 Hz, 2H, PhCH2), 2.06−1.36 (m, 10H, 5 × CH2), 0.98 (t, J
= 7.3 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ 175.4 (d,
J = 25 Hz), 157.1, 133.9, 129.1, 114.3, 88.2 (d, J = 185 Hz),
67.6, 34.6, 32.0 (d, J = 20.0 Hz), 31.3, 31.0, 23.9 (d, J = 2.5
Hz), 19.2, 13.8; 19F NMR (188 MHz, CDCl3): δ −150.4 (qt, J
= 25.6 Hz). MS (ESI) m/z (%): 281 ([M − H]−, 100); Anal.
Calcd for C16H23FO3: C, 68.06; H, 8.21; found: C, 67.93; H,
8.46.
6-(4-Butoxyphenyl)hexanoic Acid (16). Yield 95%; yellow-
ish solid; mp 198−200 °C; 1H NMR (200 MHz, CDCl3): δ
7.01 (d, J = 7.9 Hz, 2H, arom), 6.76 (d, J = 8.4 Hz, 2H, arom),
3.90 (m, 2H, CH2O), 2.70−2.33 (m, 2H, PhCH2), 2.15 (d, J =
6.6 Hz, 2H, CH2CO), 1.85−1.10 (m, 10H, CH2), 0.99 (t, J =
5.6 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ 180.7,
156.9, 134.4, 128.9, 114.0, 67.5, 36.8, 34.7, 31.2, 29.1, 25.7,
19.0, 13.6; MS (ESI) m/z (%): 263 ([M − H]−, 100); Anal.
Calcd for C16H24O3: C, 72.69; H, 9.15; found: C, 72.51; H,
9.29.
4-([1,1′-Biphenyl]-4-yl)-2-hydroxybutanoic Acid (20).
Yield 90%; white solid;. mp 189−191 °C; 1H NMR (200
MHz, CDCl3): δ 7.64−7.19 (m, 9H, arom), 4.18−4.10 (m,
1H, CH), 2.80 (t, J = 7.4 Hz, 2H, PhCH2), 2.23−1.83 (m, 2H,
CH2);
13C NMR (50 MHz, CDCl3): δ 177.8, 142.2, 141.7,
140.1, 138.7, 129.9, 129.7, 128.0, 127.7, 70.6, 37.2, 31.9; MS
(ESI) m/z (%): 255 ([M − H]−, 100); Anal. Calcd for
C16H16O3: C, 74.98; H, 6.29; found: C, 74.78; H, 6.42
General Procedure for Synthesis of 23a−d and 26a,b. To
a stirred solution of carboxylic acid (1 mmol) in tetrahy-
drofuran (THF) (6 mL) and 20% aqueous solution CsCO3
(1.1 mmol, 1.8 mL) were added and left stirring for 10 min at
80 °C. The organic solvent was evaporated under reduced
pressure and the residue was dissolved in N,N-dimethylforma-
mide (DMF) (15 mL). Subsequently, the appropriate tert-
butyl 5-bromoalkanoate, 22a or 22b (1.2 mmol), was added
and the reaction mixture was left vigorously stirring under
reflux for 72 h. The reaction mixture was concentrated in
vacuo and then water (20 mL) was added and extracted with
EtOAc (2 × 20 mL). The organic phase was dried (Na2SO4)
and concentrated under reduced pressure. The residue was
purified by flash column chromatography using EtOAc/
petroleum ether (bp 40−60 °C) 3:7 or 2:8.
5-(tert-Butoxy)-5-oxopentyl 6-(4-butoxyphenyl)-2-hydrox-
yhexanoate (23a). Yield 35%; yellowish oil; 1H NMR (200
MHz, CDCl3): δ 7.06 (d, J = 8.5 Hz, 2H, arom), 6.79 (d, J =
8.6 Hz, 2H, arom), 4.19−4.11 (m, 3H, CH, CH2OCO), 3.92
(t, J = 6.4 Hz, 2H, CH2O), 2.81 (d, J = 5.8 Hz, 1H, OH),
2.60−2.48 (m, 2H, PhCH2), 2.24 (t, J = 6.9 Hz, 2H, CH2CO),
1.86−1.36 [m, 23H, 7 × CH2, C(CH3)3], 0.95 (t, J = 7.3 Hz,
3H, CH3);
13C NMR (50 MHz, CDCl3): δ 175.6, 172.8, 157.4,
134.5, 129.4, 114.5, 80.6, 70.6, 67.9, 65.5, 35.1, 34.5, 31.7, 31.6,
28.3, 28.1, 24.7, 21.7, 19.5, 14.1; MS (ESI) m/z (%): 459 ([M
+ Na]+, 100); Anal. Calcd for C25H40O6: C, 68.78; H, 9.24;
found: C, 68.51; H, 9.42.
5-(tert-Butoxy)-5-oxopentyl 6-(4-(hexyloxy)phenyl)-2-hy-
droxyhexanoate (23b). Yield 49%; colorless oil; 1H NMR
(200 MHz, CDCl3): δ 7.05 (d, J = 8.7 Hz, 2H, arom), 6.79 (d,
J = 8.7 Hz, 2H, arom), 4.23−4.04 (m, 3H, CHOH, CH2O),
3.91 (t, J = 6.5 Hz, 2H, OCH2), 2.82 (brs, 1H, OH), 2.54 (t, J
= 7.0 Hz, 2H, PhCH2), 2.41 (t, J = 7.0 Hz, 2H, CH2CO),
1.89−1.10 [m, 27H, 9 × CH2, C(CH3)3], 0.89 (t, J = 6.6 Hz,
3H, CH3);
13C NMR (50 MHz, CDCl3): δ 175.3, 172.5, 157.1,
134.2, 129.1, 114.2, 80.3, 70.3, 67.9, 65.2, 34.8, 34.2, 31.5, 31.4,
29.2, 28.0, 27.8, 25.7, 24.4, 22.6, 21.4, 14.0; MS (ESI) m/z
(%): 487 ([M + Na]+, 100); Anal. Calcd for C27H44O6: C,
69.79; H, 9.55; found: C, 69.62; H, 9.72.
tert-Butyl 5-((4-([1,1′-Biphenyl]-4-yl)-2-hydroxybutanoyl)-
oxy)pentanoate (23c). Yield 36%; colorless oil; 1H NMR
(200 MHz, CDCl3): δ 7.62−7.22 (m, 9H, arom), 4.28−4.04
(m, 3H, OCH2, CH), 2.82−2.78 (m, 3H, PhCH2, OH), 2.33−
1.94 (m, 4H, CH2), 1.77−1.57 (m, 4H, 2 × CH2), 1.44 (s, 9H,
C(CH3)3);
13C NMR (50 MHz, CDCl3): δ 175.1, 172.5,
140.9, 140.2, 138.9, 129.0, 128.7, 127.1, 127.0, 126.9, 80.3,
69.6, 65.3, 35.9, 34.8, 30.6, 28.0, 27.8, 21.4; MS (ESI) m/z
(%): 430 ([M + NH4]
+, 100); Anal. Calcd for C25H32O5: C,
72.79; H, 7.82; found: C, 72.65; H, 7.98.
4-(tert-Butoxy)-4-oxobutyl 4-([1,1′-biphenyl]-4-yl)-2-hy-
droxybutanoate (23d). Yield 29%; colorless oil; 1H NMR
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(200 MHz, CDCl3): δ 7.64−7.22 (m, 9H, arom), 4.27−4.05
(m, 3H, OCH2, CH), 2.83−2.78 (m, 3H, PhCH2, OH), 2.30
(t, J = 7.2 Hz, 2H, CH2CO), 2.09−1.86 (m, 4H, 2 × CH2),
1.44 [m, 9H, C(CH3)3];
13C NMR (50 MHz, CDCl3): δ
175.0, 172.4, 141.0, 140.4, 138.7, 129.1, 128.6, 127.2, 127.1,
126.8, 80.4, 69.7, 65.2, 35.7, 34.6, 31.6, 28.2, 21.3; MS (ESI)
m/z (%): 421 ([M + Na]+, 100); Anal. Calcd for C24H30O5: C,
72.34; H, 7.59; found: C, 72.16; H, 7.75.
5-(tert-Butoxy)-5-oxopentyl 6-(4-butoxyphenyl)-2-fluoro-
hexanoate (26a). Yield 41%; yellowish oil; 1H NMR (200
MHz, CDCl3): δ 7.06 (d, J = 8.6 Hz, 2H, arom), 6.80 (d, J =
8.7 Hz, 2H, arom), 5.03−4.71 (dt, J = 48.0 Hz, J = 6.4 Hz, 1H,
CHF), 4.20−4.06 (m, 2H, CH2OCO), 3.92 (t, J = 6.5 Hz, 1H,
CH2O), 2.60−2.45 (m, 1H, PhCH2), 2.24 (t, J = 6.6 Hz, 2H,
CH2CO), 2.01−1.23 [m, 23H, 7 × CH2, C(CH3)3], 0.96 (t, J
= 7.3 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ 172.4,
169.9 (d, J = 23.9 Hz), 157.2, 133.8, 129.1, 114.19, 88.8 (d, J =
184.1 Hz), 80.2, 67.5, 64.9, 34.8, 34.6, 32.2 (d, J = 20.9 Hz),
31.3, 31.1, 28.0, 27.8, 23.9, 21.3, 19.2, 13.8; 19F NMR (188
MHz, CDCl3): δ −149.9 (qt, J = 24.4 Hz); MS (ESI) m/z
(%): 456 ([M + NH4]
+, 100); Anal. Calcd for C25H39FO5: C,
68.47; H, 8.96; found: C, 68.31; H, 9.12.
5-(tert-Butoxy)-5-oxopentyl 6-(4-butoxyphenyl)-
hexanoate (26b). Yield 52%; yellowish oil; 1H NMR (200
MHz, CDCl3): δ 7.03 (d, J = 8.5 Hz, 2H, arom), 6.78 (d, J =
8.6 Hz, 2H, arom), 4.05 (m, 2H, CH2OCO), 3.89 (t, J = 6.4
Hz, 2H, CH2O), 2.51 (t, J = 7.5 Hz, 2H, PhCH2), 2.33−2.10
(m, 4H, 2 × CH2CO), 1.81−1.16 [m, 23H, 7 × CH2,
C(CH3)3], 0.94 (t, J = 7.3 Hz, 3H, CH3).
13C NMR (50 MHz,
CDCl3): δ 173.4, 172.3, 157.0, 134.0, 128.9, 114.0, 79.8, 67.3,
63.5, 34.7, 34.5, 33.9, 31.2, 31.1, 28.4, 27.8, 27.8, 24.6, 21.3,
19.0, 13.6; MS (ESI) m/z (%): 443 ([M + Na]+, 100); Anal.
Calcd for C25H40O5: C, 71.39; H, 9.59; found: C, 71.19; H,
9.71.
General Procedure for Oxidation of 2-Hydroxy Esters. To
a stirring solution of 2-hydroxy esters 12 and 23a−d (1 mmol)
in dry CH2Cl2 (10 mL), Dess−Martin periodinane (1.1 mmol,
0.47 g) was added and the reaction mixture was stirred for 1.5
h at room temperature. The organic phase was washed with a
mixture of Na2S2O3 10% and NaHCO3 10% (15 mL, 1:1, v/v)
and then with brine, dried over Na2SO4, and concentrated
under reduced pressure. The residue was purified by flash
column chromatography using EtOAc−petroleum ether (bp
40−60 °C) 2:8 as eluent.
5-(tert-Butoxy)-5-oxopentyl 6-(4-butoxyphenyl)-2-oxo-
hexanoate (24a). Yield 75%; yellowish oil; 1H NMR (200
MHz, CDCl3): δ 7.05 (d, J = 8.6 Hz, 2H, arom), 6.79 (d, J =
8.6 Hz, 2H, arom), 4.23 (t, J = 6.1 Hz, 2H, CH2OCOCO),
3.91 (t, J = 6.4 Hz, 2H, CH2O), 2.83 (t, J = 6.5 Hz, 2H,
CH2COCO), 2.55 (t, J = 6.6 Hz, 2H, PhCH2), 2.25 (t, J = 6.8
Hz, 2H, CH2COO), 1.82−1.23 [m, 21H, 6 × CH2, C(CH3)3],
0.95 (t, J = 7.3 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ
194.6, 172.7, 161.4, 157.5, 134.0, 129.4, 114.5, 80.6, 67.8, 66.1,
39.4, 35.0, 34.9, 31.6, 31.1, 28.3, 28.0, 22.7, 21.6, 19.5, 14.1;
MS (ESI) m/z (%): 452 ([M + NH4]
+, 100); Anal. Calcd for
C25H38O6: C, 69.10; H, 8.81; found: C, 68.97; H, 8.99.
5-(tert-Butoxy)-5-oxopentyl 6-(4-(hexyloxy)phenyl)-2-ox-
ohexanoate (24b). Yield 79%; colorless oil; 1H NMR (200
MHz, CDCl3): δ 7.05 (d, J = 8.6 Hz, 2H, arom), 6.79 (d, J =
8.6 Hz, 2H, arom), 4.23 (t, J = 6.2 Hz, 2H, CH2OCO), 3.91 (t,
J = 6.5 Hz, 2H, OCH2), 2.83 (t, J = 6.0 Hz, 2H, CH2COCO),
2.55 (t, J = 6.2 Hz, 2H, PhCH2), 2.25 (t, J = 7.1 Hz, 2H,
CH2COO), 1.84−1.53 (m, 10H, CH2), 1.43 [s, 9H,
C(CH3)3], 1.38−1.19 (m, 6H, CH2), 0.89 (t, J = 6.3 Hz,
3H, CH3);
13C NMR (50 MHz, CDCl3): δ 194.3, 172.4, 161.1,
157.2, 133.7, 129.1, 114.3, 80.3, 67.9, 65.9, 39.1, 34.8, 34.6,
31.6, 30.8, 29.2, 28.0, 27.7, 25.7, 22.6, 22.4, 21.3, 14.0; MS
(ESI) m/z (%): 480 ([M + NH4]
+, 100); Anal. Calcd for
C27H42O6: C, 70.10; H, 9.15; found: C, 69.91; H, 9.32.
tert-Butyl 5-((4-([1,1′-Biphenyl]-4-yl)-2-oxobutanoyl)oxy)-
pentanoate (24c). Yield 70%; yellowish oil; 1H NMR (200
MHz, CDCl3): δ 7.67−7.22 (m, 9H, arom), 4.25 (t, J = 6.2 Hz,
2H, CH2OCOCO), 3.22 (t, J = 6.9 Hz, 2H, CH2COCO), 3.00
(t, J = 7.1 Hz, 2H, PhCH2), 2.26 (t, J = 7.1 Hz, 2H, CH2CO),
1.84−1.57 (m, 4H, 2 × CH2), 1.44 [s, 9H, C(CH3)3]; 13C
NMR (50 MHz, CDCl3): δ 193.3, 172.4, 160.8, 140.8, 139.3,
139.1, 128.8, 128.7, 127.2, 127.1, 126.9, 80.3, 66.0, 40.9, 34.8,
28.5, 28.0, 27.7, 21.3; MS (ESI) m/z (%): 428 ([M + NH4]
+,
100); Anal. Calcd for C25H30O5: C, 73.15; H, 7.37; found: C,
73.01; H, 7.59.
4-(tert-Butoxy)-4-oxobutyl 4-([1,1′-biphenyl]-4-yl)-2-oxo-
butanoate (24d). Yield 73%; colorless oil; 1H NMR (200
MHz, CDCl3): δ 7.65−7.21 (m, 9H, arom), 4.28 (t, J = 6.4 Hz,
2H, CH2OCOCO), 3.22 (t, J = 6.9 Hz, 2H, CH2COCO), 2.99
(t, J = 7.2 Hz, 2H, PhCH2), 2.33 (t, J = 7.2 Hz, 2H, CH2CO),
2.09−1.91 (m, 2H, CH2), 1.43 [s, 9H, 3 × CH3]; 13C NMR
(50 MHz, CDCl3): δ 194.5, 172.8, 159.8, 140.4, 139.4, 139.1,
128.9, 128.7, 127.4, 127.2, 126.8, 80.2, 65.1, 39.9, 34.6, 28.4,
28.2, 21.5; MS (ESI) m/z (%): 414 ([M + NH4]
+, 100); Anal.
Calcd for C24H28O5: C, 72.71; H, 7.12; found: C, 72.50; H,
7.34.
Methyl 6-(4-Butoxyphenyl)-2-oxohexanoate (28). Yield
60%; colorless oil; 1H NMR (200 MHz, CDCl3): δ 7.07 (d, J =
8.6 Hz, 2H, arom), 6.81 (d, J = 8.6 Hz, 2H, arom), 3.93 (t, J =
6.5 Hz, 2H, CH2O), 3.85 (s, 3H, CH3O), 2.86 (t, J = 6.9 Hz,
2H, CH2CO), 2.57 (t, J = 6.9 Hz, 2H, PhCH2), 1.82−1.40 (m,
8H, 4 × CH2), 0.97 (t, J = 7.3 Hz, 3H);
13C NMR (50 MHz,
CDCl3): δ 194.4, 161.7, 157.5, 134.0, 129.4, 114.5, 67.8, 53.2,
39.4, 34.9, 31.6, 31.1, 22.7, 19.5, 14.1; MS (ESI) m/z (%): 310
([M + NH4]
+, 100); Anal. Calcd for C17H24O4: C, 69.84; H,
8.27; found: C, 69.61; H, 8.38.
General Procedure for Cleavage of tert-Butyl Protecting
Group. A solution of tert-butyl esters 24a−d, 26a,b (1 mmol)
in CH2Cl2 (5 mL), and trifluoroacetic acid (TFA) (5 mL) was
stirred for 1 h at room temperature. The organic solvent was
evaporated under reduced pressure and then toluene (5 mL)
was added and re-evaporated twice. The product was purified
by precipitation with a mixture of EtOAc and petroleum ether
(bp 40−60 °C) (5:95, v/v) or by column chromatography
(CH2Cl2−MeOH, 95:5).
5-((6-(4-Butoxyphenyl)-2-oxohexanoyl)oxy)pentanoic
Acid (25a). Yield 72%; white solid; mp 55−58 °C. 1H NMR
(200 MHz, CDCl3): δ 7.07 (d, J = 8.6 Hz, 2H, arom), 6.81 (d,
J = 8.6 Hz, 2H, arom), 4.25 (t, J = 6.0 Hz, 2H, CH2OCO),
3.93 (t, J = 6.5 Hz, 2H, CH2O), 2.84 (t, J = 6.8 Hz, 2H,
CH2COCO), 2.57 (t, J = 6.8 Hz, 2H, PhCH2), 2.41 (t, J = 6.8
Hz, 2H, CH2COOH), 1.83−1.38 (m, 12H, 6 × CH2), 0.96 (t,
J = 7.3 Hz, 3H); 13C NMR (50 MHz, CDCl3): δ 194.2, 179.3,
161.1, 157.2, 133.7, 129.1, 114.3, 67.6, 65.7, 39.1, 34.6, 33.3,
31.3, 30.8, 27.6, 22.4, 20.9, 19.2, 13.8; HRMS (ESI) m/z: [M
− H]− Calcd for C21H29O6− 377.1970; found 377.1961; Anal.
Calcd for C21H30O6: C, 66.65; H, 7.99; found: C, 66.37; H,
8.16.
5-((6-(4-(Hexyloxy)phenyl)-2-oxohexanoyl)oxy)pentanoic
Acid (25b). Yield 84%; white solid; mp 69−71 °C; 1H NMR
(200 MHz, CDCl3): δ 7.06 (d, J = 8.3 Hz, 2H, arom), 6.80 (d,
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J = 8.6 Hz, 2H, arom), 4.25 (t, J = 5.6 Hz, 2H, CH2OCO),
3.91 (t, J = 6.5 Hz, 2H, OCH2), 2.84 (t, J = 5.7 Hz, 2H,
CH2COCO), 2.55 (t, J = 6.7 Hz, 2H, PhCH2), 2.40 (t, J = 6.6
Hz, 2H, CH2COOH), 1.94−1.09 (m, 16H, CH2), 0.89 (t, J =
5.6 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3): δ 194.3,
179.2, 161.1, 157.2, 133.7, 129.2, 114.3, 67.9, 65.7, 39.1, 34.6,
33.3, 31.6, 30.8, 29.2, 27.6, 25.7, 22.6, 22.4, 20.9, 14.0; HRMS
(ESI) m/z: [M − H]− Calcd for C23H33O6− 405.2283; found:
405.2253; Anal. Calcd for C23H34O6: C, 67.96; H, 8.43; found:
C, 67.79; H, 8.67.
5-((4-([1,1′-Biphenyl]-4-yl)-2-oxobutanoyl)oxy)pentanoic
Acid (25c). Yield 79%; white solid; mp 114−116 °C; 1H NMR
(200 MHz, CDCl3): δ 7.65−7.14 (m, 9H, arom), 4.26 (t, J =
6.1 Hz, 2H, CH2OCOCO), 3.22 (t, J = 6.5 Hz, 2H, CH2CO),
3.00 (t, J = 7.2 Hz, 2H, PhCH2), 2.40 (t, J = 6.9 Hz, 2H,
CH2COOH), 1.90−1.59 (m, 4H, CH2); 13C NMR (50 MHz,
CDCl3): δ 193.3, 179.2, 160.8, 140.8, 139.3, 139.1, 128.8,
128.7, 127.3, 127.1, 126.9, 65.8, 40.9, 33.3, 28.5, 27.6, 20.9;
HRMS (ESI) m/z: [M − H]− Calcd for C21H21O5− 353.1394;
found: 353.1388; Anal. Calcd for C21H22O5: C, 71.17; H, 6.26;
found: C, 70.95; H, 6.44.
4-((4-([1,1′-Biphenyl]-4-yl)-2-oxobutanoyl)oxy)butanoic
Acid (25d). Yield 85%; white solid; mp 137−139 °C; 1H NMR
(200 MHz, CDCl3): δ 7.63−7.20 (m, 9H, arom), 4.30 (t, J =
6.1 Hz, 2H, CH2OCOCO), 3.20 (t, J = 7.4 Hz, 2H, CH2CO),
2.99 (t, J = 7.2 Hz, 2H, PhCH2), 2.48 (t, J = 7.2 Hz, 2H,
CH2COOH), 2.14−1.96 (m, 2H, CH2); 13C NMR (50 MHz,
CDCl3): δ 193.8, 179.7, 161.3, 141.2, 139.8, 139.6, 129.3,
129.2, 127.8, 127.6, 127.5, 65.2, 40.9, 29.7, 28.5, 23.4; HRMS
(ESI) m/z: [M − H]− Calcd for C20H19O5− 339.1238; found:
339.1234; Anal. Calcd for C20H20O5: C, 70.58; H, 5.92; found:
C, 70.41; H, 6.15.
5-((6-(4-Butoxyphenyl)-2-fluorohexanoyl)oxy)pentanoic
Acid (27a). Yield 72%; low-melting-point yellow solid; 1H
NMR (200 MHz, CDCl3): δ 7.07 (d, J = 8.6 Hz, 2H, arom),
6.81 (d, J = 8.6 Hz, 2H, arom), 4.88 (dt, J = 48.0 Hz, J = 6.4
Hz, 1H, CHF), 4.20 (t, J = 5.6 Hz, 2H, CH2OCO), 3.93 (t, J =
6.5 Hz, 2H, CH2O), 2.56 (t, J = 7.3 Hz, 2H, PhCH2), 2.40 (t, J
= 6.6 Hz, 2H, CH2COOH), 2.07−1.35 (m, 14H, 7 × CH2),
0.97 (t, J = 7.3 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3) δ
179.3, 170.1 (d, J = 23.9 Hz), 157.2, 133.9, 129.1, 114.2, 88.8
(d, J = 184.1 Hz), 67.6, 64.8, 34.6, 33.3, 32.2 (d, J = 21.0 Hz),
31.3, 31.1, 27.7, 23.9 (d, J = 3 Hz), 20.9, 19.2, 13.8; 19F NMR
(188 MHz, CDCl3) δ −149.9 (qt, J = 24.4 Hz); HRMS (ESI)
m/z: [M − H]− Calcd for C21H30FO5− 381.2083; found:
381.2080; Anal. Calcd for C21H31FO5: C, 65.95; H, 8.17;
found: C, 65.76; H, 8.31.
5-((6-(4-Butoxyphenyl)hexanoyl)oxy)pentanoic Acid
(27b). Yield 99%; low-melting-point yellowish solid; 1H
NMR (200 MHz, CDCl3): δ 11.05 (s, 1H, COOH), 7.07
(d, J = 8.6 Hz, 2H, arom), 6.81 (d, J = 8.6 Hz, 2H, arom), 4.08
(t, J = 5.7 Hz, 2H, CH2OCO), 3.93 (t, J = 6.5 Hz, 2H, CH2O),
2.56 (t, J = 6.0 Hz, 2H, PhCH2), 2.45−2.22 (m, 4H, 2 × CH2),
1.85−1.20 (m, 14H, 7 × CH2), 0.97 (t, J = 7.3 Hz, 3H, CH3);
13C NMR (50 MHz, CDCl3) δ 179.4, 173.9, 157.1, 134.2,
129.1, 114.1, 67.5, 63.6, 34.7, 34.1, 33.4, 31.3, 31.2, 28.6, 27.8,
24.7, 21.1, 19.2, 13.8; HRMS (ESI) m/z: [M − H]− Calcd for
C21H31O5
− 363.2177; found: 363.2174; Anal. Calcd for
C21H32O5: C, 69.20; H, 8.85; found: C, 69.01; H, 8.99.
6-(4-Butoxyphenyl)-2-oxohexanoic Acid (29). To a stirring
solution of methyl ester 28 (1 mmol) in MeOH (10 mL), 20%
aqueous solution of Cs2CO3 (2 mmol, 3.3 mL) was added and
the mixture was stirred at room temperature overnight. The
solvent was evaporated under reduced pressure and the residue
was dissolved in H2O (10 mL) and extracted with Et2O (3 ×
10 mL). The aqueous layer was then acidified with 2 N HCl
(4.0 mL) and extracted with EtOAc (3 × 10 mL), followed by
drying over Na2SO4 and concentrating in vacuo. Yield 94%;
white solid; mp 102−105 °C; 1H NMR (200 MHz, CDCl3): δ
8.44 (s, 1H), 7.07 (d, J = 8.4 Hz, 2H, arom), 6.82 (d, J = 8.5
Hz, 2H, arom), 3.94 (t, J = 6.5 Hz, 2H, CH2O), 2.94−2.61 (m,
1H, CHH), 2.57−2.21 (m, 3H, PhCH2, CHH), 1.83−1.18 (m,
8H, 4 × CH2), 0.97 (t, J = 7.3 Hz, 3H);
13C NMR (50 MHz,
CDCl3): δ 195.4, 157.3, 133.6, 129.2, 114.3, 114.3, 67.6, 37.6,
34.5, 31.3, 30.8, 22.4, 19.2, 13.9; HRMS (ESI) m/z: [M − H]
− Calcd for C16H21O4
− 277.1445; found: 277.1444; Anal.
Calcd for C16H22O4: C, 69.04; H, 7.97; found: C, 68.89; H,
8.21.
In Vitro PLA2 Activity Assays. Group-specific mixed
micelle modified Dole assays were employed to determine the
activity of human recombinant GIVA cPLA2, GVIA iPLA2, and
GV sPLA2.
18−20 To achieve optimum activity, the substrate
was prepared using slightly different conditions for each
enzyme: (i) GIVA cPLA2 mixed micelle substrate consisted of
400 μM Triton X-100, 95.3 μM PAPC, 1.7 μM arachidonyl-
1-14C PAPC, and 3 μM PIP2 in a buffer containing 100 mM N-
(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES)
pH 7.5, 90 μM CaCl2, 2 mM dithiothreitol (DTT), and 0.1
mg/mL bovine serum albumin; (ii) GVIA iPLA2 mixed micelle
substrate consisted of 400 μM Triton X-100, 98.3 μM PAPC,
and 1.7 μM arachidonyl-1-14C PAPC in a buffer containing
100 mM HEPES pH 7.5, 2 mM adenosine 5′-triphosphate, and
4 mM DTT; and (iii) GV sPLA2 mixed micelles substrate
consisted of 400 μM Triton X-100, 98.3 μM PAPC, and 1.7
μM arachidonyl-1-14C PAPC in a buffer containing 50 mM
Tris−HCl pH 8.0, and 5 mM CaCl2. Initially, the compounds
were screened at 0.091 mol fraction (5 μL of 5 mM inhibitor in
dimethyl sulfoxide) in substrate (495 μL). XI(50) values were
determined for compounds exhibiting more than 95%
inhibition. Inhibition curves were generated using GraphPad
Prism 5.0 and the nonlinear regression by plotting percentage
of inhibition vs log (mole fraction) to calculate the reported
XI(50) and its associated error.
Plasma Stability Studies. The reactions were initiated by
the addition of test compound to 200 μL of preheated (37 °C)
human plasma to yield a final concentration of 1 mg/mL.
Samples (50 μL) were taken at 0, 15, 30, and 60 min and
acetonitrile (200 μL) was added. The samples were subjected
to vortex mixing and then centrifugation for 5 min. The clear
supernatants were analyzed by LC-HRMS/MS using an AB
Sciex 4600 Triple TOF combined with a micro-LC Eksigent
and an autosampler. Electrospray ionization (ESI)negative
modewas used for the MS experiments. Halo C18 2.7 μm,
90 Å, 0.5 × 50 mm2 from Eksigent was used as a column and
the mobile phase consisted of a gradient (A: acetonitrile/
0.01% formic acidisopropanol 80/20 v/v; B: H2O/0.01%
formic acid). The data acquisition was carried out with
MultiQuant from AB SCIEX (version 3.0). Each sample was
studied in triplicate. The plot of the percentage of the
remaining compound in comparison to the initial concen-
tration vs time was designed.
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